Biopharma Blood Cancer Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma Blood Cancer Therapeutics
1.1 - About Biopharma Blood Cancer Therapeutics sector
Companies in Biopharma Blood Cancer Therapeutics research, develop, manufacture, and commercialize treatments for hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. They deliver targeted small molecules, biologics, and cell therapies that improve response rates and survival while expanding options for refractory disease. These vendors combine clinical development expertise with GMP manufacturing and market access capabilities to bring innovative therapies to providers, payers, and patients.
Offerings span monoclonal antibodies and antibody-drug conjugates targeting CD19, CD20 or BCMA; bispecific T-cell engagers; autologous CAR-T therapies; and small-molecule inhibitors such as BTK, BCL-2, FLT3 and proteasome inhibitors for hematologic malignancies. Companies also run Phase I-III clinical programs, manage CMC and GMP biologics manufacturing, execute regulatory submissions and pharmacovigilance, and provide specialty distribution, cold-chain logistics, and patient assistance to support safe, scalable delivery of Biopharma Blood Cancer Therapeutics.
Primary customers include hospital cancer centers, community hematology-oncology practices, specialty pharmacies, and payer organizations. These companies enable broader treatment choice for relapsed or refractory disease, higher overall and complete response rates, improved progression-free survival, and better adherence through patient support. Operationally, they deliver reliable supply, standardized protocols, and real-world evidence that supports formulary access and value-based contracting.
2. Buyers in the Biopharma Blood Cancer Therapeutics sector
2.1 Top strategic acquirers of Biopharma Blood Cancer Therapeutics companies
Orca Bio
- Description: Provider of high-precision investigational cell therapies that use proprietary mixes of natural immune and stem cells, created with single-cell precision to replace diseased blood and immune systems, supported by an in-house 100,000-sq-ft facility enabling donor-to-patient delivery in 72 hours.
- Key Products:
- Investigational High-Precision Cell Therapies: Proprietary compositions of natural immune and stem cells that replace diseased blood and immune systems, aiming for balanced immune reconstitution and lower relapse, infection and GvHD
- Single-Cell Platform Technology: Process that isolates and combines cells with single-cell precision to create uniquely-defined allogeneic therapy products that integrate seamlessly into existing treatment workflows
- Centralized 100,000-sq-ft Manufacturing Facility: In-house plant delivering high-precision cell therapies at scale with donor-to-patient vein-to-vein turnaround times of 72 hours or less, ensuring consistent, reliable supply.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma Blood Cancer Therapeutics sector
M&A buyer group 1: Cancer Immunotherapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma Blood Cancer Therapeutics sector
3.1 - Buyout funds in the Biopharma Blood Cancer Therapeutics sector
2.2 - Strategic buyer groups for Biopharma Blood Cancer Therapeutics sector
4 - Top valuation comps for Biopharma Blood Cancer Therapeutics companies
4.2 - Public trading comparable groups for Biopharma Blood Cancer Therapeutics sector
Valuation benchmark group 1: Targeted Oncology Biopharma Companies
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.